DNDi E-news
July 2014   |   View Online

Viewpoint by Dr. Wilfried Mutombo, Coordinating investigator, Fexinidazole study for HAT

Conducting clinical trials for sleeping sickness in remote areas of the Democratic Republic of the Congo – Overcoming operational challenges and reaping health system benefits

At the time DNDi and its partners are extending the clinical trial on fexinidazole, the first new oral treatment tested for sleeping sickness, to the early stages of the disease in adults and to children between 6 and 14 years of age, it is important to remember how clinical trials in remote areas of a country such as the Democratic Republic of the Congo (DRC) can be a daunting challenge, but can also bring lasting benefits to local communities and researchers, and to the health system overall. »

Fexinidazole study for sleeping sickness extended to new patient groups

Following the initial results of the fexinidazole clinical trial for late-stage sleeping sickness patients, the study has been extended to both adult patients with early stages of the disease and to children between 6 and 14 years of age. »

DNDi takes part in first anniversary of Japan’s innovative GHIT Fund

In Tokyo on June 6, DNDi’s Executive Director, Bernard Pécoul spoke at the one-year anniversary event of the Japan-driven Global Health Innovative Technology (GHIT) Fund, the first product development fund for global health R&D. »

WHA shows progress in sustainable R&D financing and coordination for neglected patients

At the 67th World Health Assembly (WHA) in Geneva in May, political consensus and initial financial commitments set the stage for publicly-led R&D to bridge innovation and access to essential health tools in developing countries. »

Close up: neglected filarial diseases that affect millions

DNDi travelled to rural Ghana to document river blindness and elephantiasis, which affect over 150 million in sub-Saharan Africa, Asia, and Latin America, devastating lives through severe debilitation and social discrimination. »


BMC Infectious Diseases:
Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment »

Malaria Journal:
Population pharmacokinetics of mefloquine, administered as a fixed-dose combination of artesunate-mefloquine in Indian patients for the treatment of acute uncomplicated Plasmodium falciparum malaria »

Antimicrobial Agents and Chemotherapy:
Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease »
Photo credits : DNDi/Sylvain Cherkaoui, DNDi/Fabio Nascimento
WHA presenta avances en la financiación y la coordinación sostenible de la I + D para pacientes olvidados »

WHA apresenta avanços em financiamento e coordenação sustentáveis de P&D para pacientes negligenciados »

7th EDCTP Forum
Berlin, Germany
30 June - 2 July 2014

Satellite Meeting

Mexico City, Mexico
10 - 15 August 2014


Follow us on social media:
Twitter Facebook LinkedIn YouTube
Visit our websites:
DNDi.org  DNDiAL.org  DNDiNA.org  DNDiJapan.org  
Copyright © 2014 Drugs for Neglected Diseases initiative (DNDi), All rights reserved.
You are receiving this email because you are part of DNDi's network. You have the option to unsubscribe.

Our mailing address is:
Drugs for Neglected Diseases initiative (DNDi)
15 ch. Louis-Dunant
Geneva 1202

Add us to your address book

unsubscribe from this list    update subscription preferences